# Genentech, Inc.: Phase 1 study completed, 27 enrolled (Hepatic Impairment)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Genentech, Inc. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib |
| NCT ID | NCT07144111 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Hepatic Impairment |
| Intervention types | drug |
| Target enrollment | 27 |
| Site countries | United States |
| Posted | 2025-08-27 |
| Planned start | 2025-08-21 |
| Event | Completed |
| Event date | 2026-10-13 |
| Last update posted | 2026-10-23 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07144111). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.